Summit Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Summit Therapeutics Inc. (SMMT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are SMMT insiders buying or selling?
In the last 12 months, Summit Therapeutics Inc. insiders reported 8 open-market purchases ($114.6M) and 0 sales ($0) — net buying of $114.6M. Since November 2020, Trabud has recorded 28 Form 4 filings for SMMT: 26 buys ($783.7M) and 2 sells ($321.5K).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $50.0M by Zanganeh Mahkam (Co-Chief Executive Officer) on Jun 12, 2026. SEC ↗
- The most recent open-market purchase was reported on Jun 12, 2026 (4 months ago).
Key Statistics (November 2020 – Jun 12, 2026)
Total Form 4 filings
28
SEC EDGAR
Insider filers
6
Insider buys (26)
$783.7M
Insider sells (2)
$321.5K
Insider sentiment
Net buyingNet insider flow of $783.3M in net buying since November 2020, and $114.6M in net buying over the last 12 months.
Recent SMMT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | Purchase | 3.8M | $13.12 | $50.0M | SEC ↗ |
| Jun 12, 2026 | Robert W Duggan | Co-Chief Executive Officer | Purchase | 3.8M | $13.12 | $50.0M | SEC ↗ |
| Jun 4, 2026 | Robert W Duggan | Co-Chief Executive Officer | Purchase | 100.0K | $14.60 | $1.5M | SEC ↗ |
| Jun 4, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | Purchase | 100.0K | $14.60 | $1.5M | SEC ↗ |
| Jun 4, 2026 | Manmeet Singh Soni | COO and CFO | Purchase | 50.0K | $14.45 | $722.3K | SEC ↗ |
| Oct 24, 2025 | Yu Xia | Director | Purchase | 533.6K | $18.74 | $10.0M | SEC ↗ |
| Oct 23, 2025 | Robert W Duggan | Co-Chief Executive Officer | Purchase | 26.7K | $18.74 | $500.0K | SEC ↗ |
| Oct 23, 2025 | Zanganeh Mahkam | Co-Chief Executive Officer | Purchase | 26.7K | $18.74 | $500.0K | SEC ↗ |
| Sep 11, 2025 | Zanganeh Mahkam | Co-Chief Executive Officer | Purchase | 338.4K | $17.69 | $6.0M | SEC ↗ |
| Sep 11, 2025 | Robert W Duggan | Co-Chief Executive Officer | Purchase | 338.4K | $17.69 | $6.0M | SEC ↗ |
| Mar 28, 2024 | Zanganeh Mahkam | Chief Executive Officer | Purchase | 110.3K | $3.73 | $411.1K | SEC ↗ |
| Mar 28, 2024 | Ankur Dhingra | Chief Financial Officer | Purchase | 100.0K | $3.75 | $375.0K | SEC ↗ |
| Dec 13, 2023 | Zanganeh Mahkam | Chief Executive Officer | Purchase | 5.0K | $2.07 | $10.3K | SEC ↗ |
| Dec 13, 2023 | Ankur Dhingra | Chief Financial Officer | Purchase | 20.4K | $2.17 | $44.3K | SEC ↗ |
| Oct 16, 2023 | Manmeet Singh Soni | Chief Operating Officer | Purchase | 3.0M | $1.68 | $5.0M | SEC ↗ |
| Mar 13, 2023 | Zanganeh Mahkam | Co-CEO & President | Purchase | 23.5M | $1.05 | $24.7M | SEC ↗ |
| Mar 9, 2023 | Zanganeh Mahkam | Co-Chief Executive Officer | Purchase | 23.5M | $1.05 | $24.7M | SEC ↗ |
| Mar 8, 2023 | Ankur Dhingra | Chief Financial Officer | Purchase | 196.4K | $1.05 | $206.2K | SEC ↗ |
| Mar 8, 2023 | Ankur Dhingra | Chief Financial Officer | Purchase | 37.7K | $0.97 | $36.6K | SEC ↗ |
| Mar 8, 2023 | Robert W Duggan | Chief Executive Officer | Purchase | 376.5M | $1.05 | $395.3M | SEC ↗ |
| Aug 18, 2022 | Robert W Duggan | Chief Executive Officer | Purchase | 94.8M | $0.97 | $92.0M | SEC ↗ |
| Aug 18, 2022 | Zanganeh Mahkam | Co-CEO & President | Purchase | 5.8M | $0.97 | $5.6M | SEC ↗ |
| Aug 17, 2022 | Ankur Dhingra | Chief Financial Officer | Purchase | 36.2K | $0.97 | $35.1K | SEC ↗ |
| May 14, 2021 | Robert W Duggan | Chief Executive Officer | Purchase | 11.4M | $5.24 | $59.6M | SEC ↗ |
| May 14, 2021 | Zanganeh Mahkam | Chief Operating Officer | Purchase | 389.1K | $5.24 | $2.0M | SEC ↗ |
Showing the 25 most recent of 28 Form 4 filings for Summit Therapeutics Inc..
Most active SMMT insiders
- Zanganeh Mahkam10 filings
- Robert W Duggan8 filings
- Ankur Dhingra5 filings
- David Jonathan Powell2 filings
- Manmeet Singh Soni2 filings
Ask anything about SMMT insider activity
Use Trabud's AI agent to query Summit Therapeutics Inc.'s Form 4 history in plain English — "Show me SMMT CEO purchases this year" or compare it against any other ticker.
Open the AI agentSMMT insider trading FAQ
Are Summit Therapeutics Inc. insiders buying or selling?
In the last 12 months, Summit Therapeutics Inc. insiders reported 8 open-market purchases ($114.6M) and 0 sales ($0) — net buying of $114.6M. Since November 2020, Trabud has recorded 28 Form 4 filings for SMMT: 26 buys ($783.7M) and 2 sells ($321.5K). Over the full record that is net buying of $783.3M.
How many insiders trade SMMT stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Summit Therapeutics Inc.. The most recent filing was accepted on Jun 12, 2026.
Where does Trabud get SMMT insider trading data?
All SMMT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.